NASDAQ:MESO - Mesoblast Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.06 +0.52 (+9.39 %)
(As of 06/22/2018 06:32 AM ET)
Previous Close$5.54
Today's Range$5.8910 - $6.6561
52-Week Range$4.74 - $8.55
Volume284,414 shs
Average Volume58,956 shs
Market Capitalization$521.71 million
P/E Ratio-6.25
Dividend YieldN/A
Beta1.96
Mesoblast logoMesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MESO
CUSIPN/A
Phone61-3-9639-6036

Debt

Debt-to-Equity Ratio0.06
Current Ratio3.46
Quick Ratio3.46

Price-To-Earnings

Trailing P/E Ratio-6.25
Forward P/E Ratio-12.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.41 million
Price / Sales236.79
Cash FlowN/A
Price / CashN/A
Book Value$6.03 per share
Price / Book1.00

Profitability

EPS (Most Recent Fiscal Year)($0.97)
Net Income$-76,810,000.00
Net Margins-256.91%
Return on Equity-11.77%
Return on Assets-9.73%

Miscellaneous

EmployeesN/A
Outstanding Shares94,170,000

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release their next quarterly earnings announcement on Tuesday, September, 4th 2018. View Earnings Estimates for Mesoblast.

What price target have analysts set for MESO?

6 equities research analysts have issued twelve-month price objectives for Mesoblast's shares. Their forecasts range from $6.00 to $23.00. On average, they expect Mesoblast's stock price to reach $15.3333 in the next year. View Analyst Ratings for Mesoblast.

What are Wall Street analysts saying about Mesoblast stock?

Here are some recent quotes from research analysts about Mesoblast stock:
  • 1. Cantor Fitzgerald analysts commented, "We rate Mesoblast Overweight. We believe the company’s platform of mesenchymal lineage cell (MLC) therapies has the potential to treat an array of diseases with currently significant unmet needs. Valuation Summary We arrive at our 12-month price target of $23/share by assessing the after-tax, risk-adjusted NPV of future cash flows from Mesoblast’s MLC platform. The probability-adjusted, fully taxed NPV (15% discount rate) of future cash flows through 2030 is $2.3 billion (~$23 per ADR), in our calculation." (6/21/2018)
  • 2. Maxim Group analysts commented, "Mesoblast reported changes to its cash position for the December quarter (FY: June 30), with a net cash outflow from operations of just $14M; this includes a €5M upfront payment from TiGenix (TIG.O – NR). Mesoblast ended the period with $47M in cash and has a $90M equity facility in place." (1/31/2018)
  • 3. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (1/23/2018)

Who are some of Mesoblast's key competitors?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 61)
  • Mr. Paul Hodgkinson MA (Hons), FCA, Chief Financial Officer (Age 50)
  • Dr. Suzanne Lipe BSc (Hons), Ph.D., LLB, VP of Operations (Age 68)
  • Mr. Jonathan Richard Symonds, Head of Corp. Fin. & Strategy (Age 59)
  • Mr. Peter Howard BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 50)

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Has Mesoblast been receiving favorable news coverage?

Headlines about MESO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mesoblast earned a news sentiment score of 0.24 on Accern's scale. They also assigned news coverage about the company an impact score of 46.20 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Princeton Capital Management LLC (0.16%) and Jane Street Group LLC (0.02%). View Institutional Ownership Trends for Mesoblast.

Which major investors are buying Mesoblast stock?

MESO stock was acquired by a variety of institutional investors in the last quarter, including Princeton Capital Management LLC and Jane Street Group LLC. View Insider Buying and Selling for Mesoblast.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $6.06.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $521.71 million and generates $2.41 million in revenue each year. The company earns $-76,810,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]


MarketBeat Community Rating for Mesoblast (MESO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  304
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.